

Quantitative Tools Development Update

CPAD Annual Meeting – October 29, 2019

Klaus Romero MD MS FCP Executive Director, Clinical Pharmacology and Quantitative Medicine CRITICAL PATH FOR ALZHEIMER'S DISEASE CRITICAL PATH INSTITUTE

CONFIDENTIAL

A Clear and Successful Pathway for **Regulatory Endorsement of QDDTs**



C-Path pioneered the pathway for **Regulatory endorsement (Fit For** Purpose) of Quantitative DDTs



SHORT REPORT

Modeling and simulation for medical product development and evaluation: highlights from the FDA-C-Path-ISOP 2013 workshop

Klaus Romero · Vikram Sinha · Sandra Allerheiligen · Meindert Danhof · Jose Pinheiro · Naomi Kruhlak · Yaning Wang · Sue-Jane Wang · John-Michael Sauer · J. F. Marier · Brian Corrigan · James Rogers · H. J. Lambers Heerspink · Tawanda Gumbo · Peter Vis · Paul Watkins · Tina Morrison · William Gillespie · Mark Forrest Gordon · Diane Stephenson · Debra Hanna · Marc Pfister · Richard Lalonde · Thomas Colatsky

	ig and I	nd Drug Administ Promoting <i>Your</i> Healtt			Search FDA	
Home Food Drugs	Martin	- Devices Devices Faith	n Bardanta Literatura	Diana & Dialacian 🗍 As		
Home Food Drugs	Medica	al Devices Radiation-Emitti	ng Products Vaccines, I	Blood & Biologics Ar	imal & Veterinary Cosme	tics Tobacco
Home > Drugs > Developme	int & App	roval Process (Drugs)				
Development & Approval Process (Drugs)		Drug Deve Initiative	elopment ⁻	Tools: Fit	-for-Purpos	se
Drug Development Tool Progr and Initiatives	ams	f CHARE Y TWEET		S EMAL 🔒 PRINT		
Guidance Documents for Dru Applications	9	Background				
Laws, Regulations, Policies a Procedures for Drug Applicat		development program	s. Due to the evolving r	nature of these types	ry acceptance of dynami of drug development too	ols (DDTs) and
Letter of Support Initiative		deemed FFP based o	n the acceptance of the	proposed tool follow	ose' (FFP) has been esta ring a thorough evaluatio ffort to facilitate greater u	n of the inform
How Drugs are Developed and Approved	~	in drug development p			non to racilitate greater t	anzation of the
Development Resources	•		about the FFP Initiative,	please contact Drug	DevelopmentTools@fda.	.hhs.gov
Conducting Clinical Trials		Fit-For-Purpose Tools	and Supporting Inform	nation:		
Forms & Submission Requirements	•					Issuance D Support
Manufacturing	~	Disease Area	Submitter	Tool	Trial Component	Informa
CDER Small Business and Industry Assistance	•	Alzheimer's disease	The Coalition Against Major Diseases (CAMD)	Disease Model: Placebo/Disease Progression	Demographics, Drop- out	Issued June Determinal Letter
Drug Innovation	•					The tool is available
Drug Development Tools Qualification Programs	•					https://bitbu metrumrg/alz disease-prog mode
Resources for You		M. St. L.	Janssen	Statistical Method	0	adascog/wil
 Drug Development Tool Programs and Initiatives 		Multiple	Pharmaceuticals and Novartis Pharmaceuticals	Statistical Method	Dose-Finding	Issued May 3
						Determinal Letter Statistical Pharmacon Review





19 September 2013 EMA/CHMP/SAWP/567188/2013 Committee for Medicinal Products for Human Use (CHMP)

Qualification opinion of a novel data driven model of disease progression and trial evaluation in mild and moderate Alzheimer's disease

Draft agreed by Scientific Advice Working Party	6 June 2013
Adopted by CHMP for release for consultation	27 June 2013 ¹
Start of public consultation	19 July 2013 ²
End of consultation (deadline for comments)	27 August 2013 ³
Adoption by CHMP	19 September 2013

http://www.ema.europa.eu/docs/en GB/document library/Regulator y and procedural quideline/2013/10/WC500151309.pdf

Regulatory Pathway Strategy (EMA)

Qualification of novel methodologies steps



Triggers the formal start of the process, and the formation of the specific scientific advice working party (SAWP)

Opportunity to optimize briefing document (tight timelines)

Triggers the first deep-dive regulatory review

Formal checkpoint to finalize the analysis plan for execution

Triggers the final deep-dive regulatory review

Final decision


CRITICAL PATH INSTITUTE

Briefing Document

- Summary
- Regulatory history
- 🔹 COU
- Modeling analysis plan:
 - Data sources and management
 - Data analytics
- Q&A: ٠.
 - Questions to the Agency
 - Consortium position on the questions

Mild-to-Moderate AD Clinical Trial Simulator

Qualification of novel methodologies steps






Briefing Document

- Summary
- Regulatory history
- COU
- Modeling analysis plan:
 - Data sources and management
 - Data analytics
- 🔅 Q&A:
 - Questions to the Agency
 - Consortium position on the questions

Predementia disease progression model with baseline HV

Qualification of novel methodologies steps





Briefing Document

- Modeling analysis plan:
 - Data sources and management
 - Questions to the Agency
 - Consortium position on the questions






18 October 2018 EMA/693969/2018 Executive Director

Letter of support for Model-based CT enrichment tool for CTs in aMCI

- The EMA supports the primary objectives of the applicant and has decided to issue a Letter of Support to the CPAD Consortium
- To encourage industry sponsors to share the patient-level data from completed phase II and III clinical trials in the intended target population as defined in the COU statement, including active and control arms, with CPAD
- To encourage the CPAD team to disseminate and provide access to the current version of the model for implementation by sponsors actively designing clinical trials

Regulatory Pathway Strategy (FDA)

Fit-for-Purpose Initiative



Triggers the formal start of the process, and the formation of the regulatory review team

Formal green light to proceed. Provides an opportunity to get early feedback. Opportunity to optimize the briefing document

Triggers deep-dive regulatory review

Formal checkpoint to finalize the analysis plan for execution

Triggers the final deep-dive regulatory review

Final decision


Briefing Document

- Summary
- Regulatory history
- COU
- Modeling analysis plan:
 - Data sources and management
 - Data analytics
- 🔅 Q&A:
 - Questions to the Agency
 - Consortium position on the questions

CRITICAL PATH FOR ALZHEIMER'S DISEASE CRITICAL PATH INSTITUTE

Mild-to-Moderate AD Clinical Trial Simulator

Fit-for-Purpose Initiative






Briefing Document

- Summary
- Regulatory history
- 🔹 COU
- Modeling analysis plan:
 - Data sources and management
 - Data analytics
- Q&A: •••
 - Questions to the Agency
 - Consortium position on the questions

Predementia disease progression model with baseline HV

Fit-for-Purpose Initiative






Briefing Document


- Summary
- Regulatory history
- COU
- Modeling analysis plan:
 - Data sources and management
 - Data analytics
- 🔅 Q&A:
 - Questions to the Agency
 - Consortium position on the questions

AD CTS: n=50

Mild-to-Moderate Alzheimer Disease Clinical Trial Simulator (beta v2.0)









Characteristics	Values
Study Design	Parallel Design
Study Duration (weeks)	52
Assessment Interval (weeks)	4
Effect of Drug on Rate of Disease Progression (% Reduction)	30
Sample size	50
Age, (mean,sd)	(74.57,1.04)
Percentage of Male (mean,sd)	(0.43,0.06)
Number of APOE e4 alleles (%)	0 (54), 1 (44)
Baseline MMSE, median (range)	(18,22)
Concomitant medication use (%)	1
Dropout: Weeks at last assessment (mean,sd)	(47.71,0.84)
Trial Power (%)	0
Monte Carlo Error (%)	0
Confidence Interval of Monte Carlo Error	(0,0)

AD CTS: n=200

Mild-to-Moderate Alzheimer Disease Clinical Trial Simulator (beta v2.0)





ʹΡΔ

CPAD

CRITICAL PATH FOR ALZHEIMER'S DISEASE CRITICAL PATH INSTITUTE


CRITICAL PATH FOR ALZHEIMER'S DISEASE


Values
Parallel Design
52
4
30
200
(75.01,0.63)
(0.45,0.03)
0 (55), 1 (45)
(18,22)
1
(48.96,0.43)
67
27
(14,120)

By Jackson Burton (model and app developer) and Daniela Conrado (model developer) on behalf of the Critical Path for Alzheimer Disease (CPAD) consortium. E-mail JBurton@c-path.org with questions or comments.

AD CTS: genetic enrichment

Mild-to-Moderate Alzheimer Disease Clinical Trial Simulator (beta v2.0)





CRITICAL PATH FOR ALZHEIMER'S DISEASE CRITICAL PATH INSTITUTE

CPAD

CRITICAL PATH FOR ALZHEIMER'S DISEASE RITICAL PATH INSTITUT

Characteristics	Values
Study Design	Parallel Design
Study Duration (weeks)	52
Assessment Interval (weeks)	4
Effect of Drug on Rate of Disease Progression (% Reduction)	30
Sample size	200
Age, (mean,sd)	(74.27,0.59)
Percentage of Male (mean,sd)	(0.42,0.02)
Number of APOE e4 alleles (%)	0 (44), 1 (45), 2 (11)
Baseline MMSE, median (range)	(18,22)
Concomitant medication use (%)	1
Dropout: Weeks at last assessment (mean,sd)	(49.11,0.59)
Trial Power (%)	33
Monte Carlo Error (%)	27
Confidence Interval of Monte Carlo Error	(-20,86)


Time (Weeks)


By Jackson Burton (model and app developer) and Daniela Conrado (model developer) on behalf of the Critical Path for Alzheimer Disease (CPAD) consortium. E-mail JBurton@c-path.org with questions or comments.

AD CTS: baseline severity!

Mild-to-Moderate Alzheimer Disease Clinical Trial Simulator (beta v2.0)









Characteristics	Values
Study Design	Parallel Design
Study Duration (weeks)	52
Assessment Interval (weeks)	4
Effect of Drug on Rate of Disease Progression (% Reduction)	30
Sample size	200
Age, (mean,sd)	(74.34,0.67)
Percentage of Male (mean,sd)	(0.39,0.02)
Number of APOE e4 alleles (%)	0 (44), 1 (45), 2 (11)
Baseline MMSE, median (range)	(19,23)
Concomitant medication use (%)	1
Dropout: Weeks at last assessment (mean,sd)	(49.19,0.17)
Trial Power (%)	0
Monte Carlo Error (%)	0
Confidence Interval of Monte Carlo Error	(0,0)

MCI/HV CTS: n=400

Hippocampal Neuroimaging-Informed Amnestic MCI Clinical Trial Simulator

Simulate clinical trials on patients with amnestic mild cognitive impairment





50 (6.8, 93.2)

Statistical Power (%, 95% Confidence Interval)

Placebo
Drug


CRITICAL PATH FOR ALZHEIMER'S DISEASE


PAD

MCI/HV CTS: baseline severity

Hippocampal Neuroimaging-Informed Amnestic MCI Clinical Trial Simulator

Simulate clinical trials on patients with amnestic mild cognitive impairment





75 (19.4, 99.4)



Placebo


PAD


Statistical Power (%, 95% Confidence Interval)

MCI/HV CTS: biomarker enrichment!

Hippocampal Neuroimaging-Informed Amnestic MCI Clinical Trial Simulator

Simulate clinical trials on patients with amnestic mild cognitive impairment





100 (39.8, 100)

CRITICAL PATH FOR ALZHEIMER'S DISEASE CRITICAL PATH INSTITUTE

CPAD

Statistical Power (%, 95% Confidence Interval)





- There is a pressing need for a better-informed basis on which to design clinical trials in neuroscience
- Science is directing us to conduct trials in even earlier stages of progressive neurological disease – the information upon which to do so is limited

VISION IN ALZHEIMER'S DISEASE AS A TEMPLATE FOR PROGRESSIVE NEUROLOGICAL DISEASES

To provide a disease progression model across the entire continuum of Alzheimer's disease (AD) – from the earliest stages to severe AD – providing an invaluable tool that will aid in optimizing trial design & execution, reduction of cost & time, and reduced patient burden



Thank you!



CONFIDENTIAL